A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.

Invest New Drugs 2015 Apr 9;33(2):371-9. Epub 2014 Dec 9.

Department of Medicine, The University of Chicago, Chicago, IL, USA,

Background We hypothesized that targeting two mechanisms of epigenetic silencing would be additive or synergistic with regard to expression of specific target genes. The primary objective of the study was to establish the maximum tolerated dose (MTD) of belinostat in combination with a fixed dose of azacitidine (AZA). Methods In Part A of the study, patients received a fixed dose of AZA, with escalating doses of belinostat given on the same days 1-5, in a 28 day cycle. Part B was designed to evaluate the relative contribution of belinostat to the combination based on analysis of pharmacodynamic markers, and incorporated a design in which patients were randomized during cycle 1 to AZA alone, or the combination, at the maximally tolerated dose of belinostat. Results 56 patients with myeloid neoplasia were enrolled. Dose escalation was feasible in part A, up to 1000 mg/m(2) dose level of belinostat. In Part B, 18 patients were assessable for quantitative analysis of specific target genes. At day 5 of therapy, MDR1 was significantly up-regulated in the belinostat/AZA arm compared with AZA alone arm (p = 0.0023). There were 18 responses among the 56 patients. Conclusions The combination of belinostat and AZA is feasible and associated with clinical activity. The recommended phase II dose is 1000 mg/m(2) of belinostat plus 75 mg/m(2) of AZA on days 1-5, every 28 days. Upregulation in MDR1 was observed in the combination arm at day 5 compared with the AZA alone arm, suggesting a relative biologic contribution of belinostat to the combination.

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007%2Fs10637-014-01
Web Search
http://link.springer.com/10.1007/s10637-014-0194-2
Publisher Site
http://dx.doi.org/10.1007/s10637-014-0194-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390421PMC
April 2015
44 Reads

Publication Analysis

Top Keywords

belinostat combination
12
belinostat
9
belinostat patients
8
fixed dose
8
tolerated dose
8
contribution belinostat
8
1000 mg/m2
8
myeloid neoplasia
8
days 1-5
8
compared aza
8
aza arm
8
specific target
8
target genes
8
aza
7
dose
7
combination
6
patients
5
combination based
4
incorporated design
4
markers incorporated
4

References

(Supplied by CrossRef)

J Chen et al.
Nat Rev Cancer 2010

PL Jones et al.
Nat Genet 1998

EE Cameron et al.
Nat Genet 1999

SA Belinsky et al.
Cancer Res 2011

N Steele et al.
Br J Cancer 2009

H Suzuki et al.
Nat Genet 2002

MI Klisovic et al.
Leukemia 2003

H Kantarjian et al.
Cancer 2006

LR Silverman et al.
J Clin Oncol 2002

LR Silverman et al.
J Clin Oncol 2006

JC Byrd et al.
Blood 2005

Similar Publications